论文部分内容阅读
目的比较评价新辅助化疗情况下,紫杉醇脂质体与紫杉醇治疗乳腺癌的疗效及毒副作用。方法检索国内外数据库,对符合纳入标准的文献进行质量评价和Meta分析。结果有4项研究纳入分析,共244例患者。紫杉醇脂质体与紫杉醇治疗乳腺癌有效性比较,合并OR值为0.9(0.54,1.50),经Z检验,P=0.69,差异无统计学意义;紫杉醇脂质体与紫杉醇治疗乳腺癌引起的不良反应中,白细胞减少合并OR值为0.96(0.58,1.60),经Z检验,P=0.89,差异无统计学意义;脱发合并OR值为0.72(0.42,1.24),经Z检验,P=0.24,差异无统计学意义;肌肉痛合并OR值为0.45(0.26,0.76),经Z检验,P=0.003,差异有统计学意义,即紫杉醇脂质体引起的肌肉痛症状更少;皮疹合并OR值为0.19(0.08,0.44),经Z检验,P=0.0001,差异有统计学意义,即紫杉醇脂质体引起的肌肉痛症状更少。结论紫杉醇脂质体与紫杉醇治疗乳腺癌疗效相当,不良反应中,血液毒性、脱发等发生率相似,但在引起肌肉痛、皮疹方面,紫杉醇脂质体相对于紫杉醇有所缓解。
Objective To evaluate the efficacy and side effects of paclitaxel liposomes and paclitaxel in the treatment of breast cancer under neoadjuvant chemotherapy. Methods Retrieve databases at home and abroad, and evaluate the quality and Meta-analysis of the documents that meet the inclusion criteria. Results Four studies were included in the analysis, a total of 244 patients. Paclitaxel liposomes and paclitaxel effective in the treatment of breast cancer, the combined OR was 0.9 (0.54,1.50), by Z test, P = 0.69, the difference was not statistically significant; paclitaxel liposomes and paclitaxel treatment of breast cancer caused by poor The OR of combined leukopenia was 0.96 (0.58,1.60), P = 0.89 by Z test, the difference was not statistically significant. The odds ratio (OR) was 0.72 (0.42,1.24) The difference was not statistically significant; the OR of muscle pain was 0.45 (0.26,0.76), P = 0.003 by Z test, the difference was statistically significant, that is, paclitaxel liposome caused less symptoms of muscular pain; rash combined OR Was 0.19 (0.08,0.44), Z test, P = 0.0001, the difference was statistically significant, that paclitaxel liposome caused less symptoms of muscle pain. Conclusions Paclitaxel liposomes have the same curative effect as paclitaxel in the treatment of breast cancer. The incidence of adverse reactions such as hematotoxicity and alopecia is similar, but paclitaxel liposome is relieved in the aspects of muscle pain and rash.